These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 31325448

  • 1. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
    Beider K, Bitner H, Voevoda-Dimenshtein V, Rosenberg E, Sirovsky Y, Magen H, Canaani J, Ostrovsky O, Shilo N, Shimoni A, Abraham M, Weiss L, Milyavsky M, Peled A, Nagler A.
    Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
    Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R.
    Invest New Drugs; 2020 Aug; 38(4):1108-1116. PubMed ID: 31654285
    [Abstract] [Full Text] [Related]

  • 3. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
    Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R.
    PLoS One; 2011 Aug; 6(11):e27178. PubMed ID: 22087262
    [Abstract] [Full Text] [Related]

  • 4. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists.
    Mandawat A, Fiskus W, Buckley KM, Robbins K, Rao R, Balusu R, Navenot JM, Wang ZX, Ustun C, Chong DG, Atadja P, Fujii N, Peiper SC, Bhalla K.
    Blood; 2010 Dec 09; 116(24):5306-15. PubMed ID: 20810927
    [Abstract] [Full Text] [Related]

  • 5. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
    Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y, Younes A.
    Blood; 2012 Apr 26; 119(17):4017-25. PubMed ID: 22408261
    [Abstract] [Full Text] [Related]

  • 6. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
    Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R.
    Oncotarget; 2013 Dec 26; 4(12):2225-36. PubMed ID: 24163230
    [Abstract] [Full Text] [Related]

  • 7. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, Zhu J.
    Int J Cancer; 2018 Jan 01; 142(1):202-213. PubMed ID: 28905990
    [Abstract] [Full Text] [Related]

  • 8. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W, Lee DH, Zheng Y, Wuensche P, Alvarez R, Wen DL, Aribi AM, Thean SM, Doan NB, Said JW, Koeffler HP.
    Mol Carcinog; 2014 Sep 01; 53(9):722-35. PubMed ID: 23475695
    [Abstract] [Full Text] [Related]

  • 9. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW, Ge Y, Wang Z.
    PLoS One; 2013 Sep 01; 8(9):e76662. PubMed ID: 24098799
    [Abstract] [Full Text] [Related]

  • 10. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
    Lin Z, Zhang Z, Jiang X, Kou X, Bao Y, Liu H, Sun F, Ling S, Qin N, Jiang L, Yang Y.
    Oncotarget; 2017 Mar 14; 8(11):17833-17848. PubMed ID: 28147319
    [Abstract] [Full Text] [Related]

  • 11. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
    Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.
    Mol Cancer Ther; 2017 Jul 14; 16(7):1389-1400. PubMed ID: 28468774
    [Abstract] [Full Text] [Related]

  • 12. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, Yao YM, Kwon P, Fawell S, Atadja P.
    Int J Cancer; 2010 Nov 01; 127(9):2199-208. PubMed ID: 20127862
    [Abstract] [Full Text] [Related]

  • 13. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 14. The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1.
    Saitoh Y, Bureta C, Sasaki H, Nagano S, Maeda S, Furukawa T, Taniguchi N, Setoguchi T.
    Mol Carcinog; 2019 Feb 31; 58(2):234-246. PubMed ID: 30303565
    [Abstract] [Full Text] [Related]

  • 15. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L.
    PLoS One; 2016 Feb 31; 11(6):e0158208. PubMed ID: 27352023
    [Abstract] [Full Text] [Related]

  • 16. Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Islam P, Rizzieri D, Lin C, de Castro C, Diehl L, Li Z, Moore J, Morris T, Beaven A.
    Cancer Invest; 2021 Nov 31; 39(10):871-879. PubMed ID: 34643126
    [Abstract] [Full Text] [Related]

  • 17. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
    Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, Kumar S.
    Leuk Res; 2014 Nov 31; 38(11):1358-66. PubMed ID: 25282334
    [Abstract] [Full Text] [Related]

  • 18. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
    Wasim L, Chopra M.
    Biomed Pharmacother; 2016 Dec 31; 84():1393-1405. PubMed ID: 27802904
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F.
    Int J Cancer; 2013 Nov 31; 133(9):2089-101. PubMed ID: 23629727
    [Abstract] [Full Text] [Related]

  • 20. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.